Cosentyx is a biologic medication that is used to treat autoimmune disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein in the body that causes inflammation [1].

According to the available sources, there is limited information on the use of Cosentyx during breastfeeding. The manufacturer's label states that it is unknown whether Cosentyx is excreted in human milk or absorbed systemically after ingestion by a nursing infant [1]. Additionally, there are no adequate studies in women for determining infant risk when using this medication during breastfeeding [2].

A study published in Frontiers in Pharmacology in 2021 analyzed the available data on the use of Cosentyx during pregnancy and lactation. The study concluded that there is insufficient data to assess the safety of Cosentyx during breastfeeding. The authors recommended that women should avoid breastfeeding while using Cosentyx [3].

In summary, the available sources suggest that there is limited information on the use of Cosentyx during breastfeeding. The manufacturer's label advises caution, and a recent study recommends that women avoid breastfeeding while using Cosentyx. It is important to consult with a healthcare provider before using any medication while breastfeeding to weigh the potential risks and benefits.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/books/NBK537091/
[3] https://www.frontiersin.org/articles/10.3389/fphar.2021.621247/full